Trial Information
Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate (MelCancerVac) for Treatment of Patients With Advanced Colorectal Cancer
Inclusion Criteria:
- Verified cancer of colon or rectum
- No chemo- or radiation therapy in 6 weeks
- Performance status 0, 1, or 2 (WHO criteria)
- Adequate function of the kidneys, liver, lungs, and heart
- Adequate function of the hematopoietic system and the coagulation system
- Negative pregnancy test and adequate birth control for fertile women
Exclusion Criteria:
- Pregnancy
- Uncontrolled infection
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Principal Investigator
Anders Fischer, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospital Gentofte
Authority:
Denmark: Danish Medicines Agency
Study ID:
2612-1970
NCT ID:
NCT00311272
Start Date:
November 2004
Completion Date:
September 2007
Related Keywords:
- Colorectal Neoplasms
- dendritic cells
- antigens, neoplasm
- Neoplasms
- Colorectal Neoplasms